These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 17485502

  • 1. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM, García-de-la-Mària C, Armero Y, de-Lazzari E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jiménez-de-Anta MT, Marco F, Hospital Clínic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG, Basuino L, Chambers HF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [Abstract] [Full Text] [Related]

  • 4. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Marco F, de la Mària CG, Armero Y, Amat E, Soy D, Moreno A, del Río A, Almela M, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM, Hospital Clinic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2538-43. PubMed ID: 18426900
    [Abstract] [Full Text] [Related]

  • 5. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW, Patron RL, Goldstein BP, Archer GL.
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1355-60. PubMed ID: 9624475
    [Abstract] [Full Text] [Related]

  • 6. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
    Xiong YQ, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang SJ.
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5528-33. PubMed ID: 22890759
    [Abstract] [Full Text] [Related]

  • 7. Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
    García-de-la-Mària C, Marco F, Armero Y, Soy D, Moreno A, del Río A, Almela M, Cervera C, Ninot S, Falces C, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM, Hospital Clínic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2781-6. PubMed ID: 20421394
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
    Entenza JM, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
    [Abstract] [Full Text] [Related]

  • 9. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK, Lynch AS.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1476-84. PubMed ID: 22232278
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
    Xiong YQ, Abdelhady W, Tang C', Bayer AS.
    J Antimicrob Chemother; 2016 Oct; 71(10):2890-4. PubMed ID: 27353467
    [Abstract] [Full Text] [Related]

  • 13. Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.
    del Río A, García-de-la-Mària C, Entenza JM, Gasch O, Armero Y, Soy D, Mestres CA, Pericás JM, Falces C, Ninot S, Almela M, Cervera C, Gatell JM, Moreno A, Moreillon P, Marco F, Miró JM, Hospital Clinic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):478-86. PubMed ID: 26525803
    [Abstract] [Full Text] [Related]

  • 14. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [Abstract] [Full Text] [Related]

  • 15. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM, Que YA, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [Abstract] [Full Text] [Related]

  • 16. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.
    Boucher HW, Thauvin-Eliopoulos C, Loebenberg D, Eliopoulos GM.
    Antimicrob Agents Chemother; 2001 Jan; 45(1):208-11. PubMed ID: 11120967
    [Abstract] [Full Text] [Related]

  • 17. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.
    Marcos LA, Camins BC.
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5376-8. PubMed ID: 20876369
    [Abstract] [Full Text] [Related]

  • 18. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.
    Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R.
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1515-8. PubMed ID: 7979281
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [Abstract] [Full Text] [Related]

  • 20. Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.
    Sacar M, Sacar S, Cevahir N, Onem G, Teke Z, Asan A, Turgut H, Adali F, Kaleli I, Susam I, Yaylali YT, Baltalarli A.
    Tex Heart Inst J; 2010 Feb; 37(4):400-4. PubMed ID: 20844611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.